NCT06104449View on ClinicalTrials.gov

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

April 12, 2026

Study Completion Date

April 12, 2026

Conditions
Prostatic NeoplasmsMetastatic Castration-Resistant Prostate Cancer
Interventions
DRUG

Opevesostat

Tablets to be taken orally.

DRUG

Dexamethasone

Tablets to be taken orally.

DRUG

Fludrocortisone acetate

Tablet to be taken orally.

DRUG

Hydrocortisone

Tablets to be taken orally as a recue medication.

Trial Locations (3)

277-8577

National Cancer Center Hospital East ( Site 0001), Kashiwa

285-8741

Toho University Sakura Medical Center ( Site 0003), Sakura

232-0024

Yokohama City University Medical Center ( Site 0002), Yokohama

All Listed Sponsors
collaborator

Orion Corporation, Orion Pharma

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06104449 - A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) | Biotech Hunter | Biotech Hunter